Nichole Carlson
Concepts (571)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis | 3 | 2026 | 160 | 1.720 |
Why?
| | Sarcoidosis, Pulmonary | 4 | 2026 | 95 | 1.610 |
Why?
| | Tomography, X-Ray Computed | 7 | 2026 | 2730 | 1.510 |
Why?
| | Bayes Theorem | 6 | 2020 | 433 | 1.160 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 190 | 1.020 |
Why?
| | Outpatients | 8 | 2025 | 442 | 0.960 |
Why?
| | Models, Statistical | 6 | 2020 | 681 | 0.910 |
Why?
| | Parkinson Disease | 5 | 2026 | 600 | 0.890 |
Why?
| | Hydrocortisone | 6 | 2015 | 304 | 0.850 |
Why?
| | Radiography, Thoracic | 3 | 2026 | 171 | 0.820 |
Why?
| | Hormones | 3 | 2017 | 134 | 0.790 |
Why?
| | Lung | 7 | 2026 | 4109 | 0.770 |
Why?
| | Emphysema | 1 | 2023 | 100 | 0.740 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 198 | 0.680 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 275 | 0.650 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 780 | 0.630 |
Why?
| | Cognitive Dysfunction | 1 | 2026 | 461 | 0.630 |
Why?
| | Diabetes Complications | 1 | 2022 | 222 | 0.630 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 372 | 0.630 |
Why?
| | Alzheimer Disease | 6 | 2026 | 621 | 0.610 |
Why?
| | Disease Susceptibility | 1 | 2021 | 348 | 0.580 |
Why?
| | Metadata | 1 | 2018 | 17 | 0.560 |
Why?
| | State Health Plans | 2 | 2008 | 28 | 0.540 |
Why?
| | Computer Simulation | 4 | 2017 | 1025 | 0.530 |
Why?
| | Humans | 105 | 2026 | 144759 | 0.520 |
Why?
| | Follicle Stimulating Hormone | 9 | 2023 | 249 | 0.510 |
Why?
| | Ovary | 3 | 2017 | 228 | 0.510 |
Why?
| | Models, Biological | 3 | 2017 | 1821 | 0.500 |
Why?
| | Middle Aged | 45 | 2026 | 35875 | 0.500 |
Why?
| | Female | 79 | 2026 | 78271 | 0.490 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 147 | 0.480 |
Why?
| | Genome | 1 | 2018 | 306 | 0.480 |
Why?
| | Reproduction | 1 | 2017 | 207 | 0.480 |
Why?
| | Adult | 58 | 2026 | 40449 | 0.470 |
Why?
| | Child Health Services | 2 | 2008 | 185 | 0.460 |
Why?
| | Residence Characteristics | 6 | 2010 | 377 | 0.450 |
Why?
| | Wound Infection | 2 | 2026 | 56 | 0.450 |
Why?
| | Aged | 32 | 2026 | 25913 | 0.450 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 18 | 0.430 |
Why?
| | Cluster Analysis | 3 | 2026 | 521 | 0.430 |
Why?
| | Health Services for the Aged | 2 | 2019 | 70 | 0.420 |
Why?
| | Adenosine Monophosphate | 2 | 2025 | 86 | 0.420 |
Why?
| | Male | 52 | 2026 | 72315 | 0.420 |
Why?
| | Biometry | 2 | 2017 | 68 | 0.420 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2021 | 653 | 0.420 |
Why?
| | Brain Injuries | 5 | 2010 | 507 | 0.410 |
Why?
| | Alanine | 2 | 2025 | 171 | 0.410 |
Why?
| | Software | 2 | 2019 | 690 | 0.410 |
Why?
| | Obesity | 12 | 2023 | 3077 | 0.410 |
Why?
| | Computational Biology | 1 | 2018 | 680 | 0.400 |
Why?
| | Pulsatile Flow | 1 | 2013 | 55 | 0.390 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 41 | 0.390 |
Why?
| | Environment Design | 3 | 2010 | 27 | 0.390 |
Why?
| | Respiratory Function Tests | 3 | 2026 | 547 | 0.380 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 50 | 0.380 |
Why?
| | Antibodies, Viral | 5 | 2024 | 672 | 0.380 |
Why?
| | Antibodies, Monoclonal | 6 | 2025 | 1519 | 0.380 |
Why?
| | Circadian Rhythm | 4 | 2013 | 514 | 0.370 |
Why?
| | Health Services Accessibility | 4 | 2010 | 1098 | 0.350 |
Why?
| | Neuropsychological Tests | 4 | 2026 | 1134 | 0.350 |
Why?
| | Gonadotropins | 3 | 2023 | 39 | 0.340 |
Why?
| | Specimen Handling | 1 | 2013 | 186 | 0.340 |
Why?
| | Antibodies, Neutralizing | 5 | 2025 | 340 | 0.340 |
Why?
| | Saliva | 1 | 2013 | 249 | 0.340 |
Why?
| | Walking | 4 | 2010 | 545 | 0.320 |
Why?
| | Antiviral Agents | 3 | 2025 | 767 | 0.320 |
Why?
| | Hospitalization | 9 | 2025 | 2433 | 0.320 |
Why?
| | White Matter | 2 | 2023 | 153 | 0.310 |
Why?
| | Levodopa | 2 | 2007 | 41 | 0.310 |
Why?
| | Oregon | 8 | 2011 | 76 | 0.310 |
Why?
| | Hypogonadism | 2 | 2015 | 90 | 0.310 |
Why?
| | Health Status | 4 | 2026 | 836 | 0.300 |
Why?
| | Endocrine System | 1 | 2009 | 22 | 0.300 |
Why?
| | Risk Factors | 12 | 2026 | 10779 | 0.300 |
Why?
| | Statistics as Topic | 3 | 2025 | 284 | 0.290 |
Why?
| | Activities of Daily Living | 3 | 2010 | 441 | 0.290 |
Why?
| | Aging | 5 | 2026 | 1966 | 0.280 |
Why?
| | Testosterone | 2 | 2010 | 419 | 0.280 |
Why?
| | Cohort Studies | 8 | 2026 | 5960 | 0.280 |
Why?
| | Technology | 1 | 2009 | 95 | 0.270 |
Why?
| | Prenatal Care | 1 | 2010 | 307 | 0.270 |
Why?
| | Aged, 80 and over | 13 | 2026 | 8265 | 0.270 |
Why?
| | Estradiol | 6 | 2023 | 533 | 0.270 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 54 | 0.270 |
Why?
| | Levonorgestrel | 4 | 2011 | 35 | 0.260 |
Why?
| | Metrorrhagia | 3 | 2011 | 4 | 0.260 |
Why?
| | Health Behavior | 3 | 2010 | 785 | 0.260 |
Why?
| | Cognition Disorders | 3 | 2008 | 538 | 0.260 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2583 | 0.260 |
Why?
| | Perception | 2 | 2007 | 377 | 0.250 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 58 | 0.250 |
Why?
| | Spirometry | 3 | 2026 | 231 | 0.250 |
Why?
| | Methylphenidate | 1 | 2007 | 49 | 0.250 |
Why?
| | Smoking Cessation | 1 | 2010 | 439 | 0.250 |
Why?
| | Young Adult | 15 | 2024 | 14105 | 0.240 |
Why?
| | War-Related Injuries | 1 | 2026 | 46 | 0.230 |
Why?
| | Time Factors | 13 | 2017 | 7173 | 0.220 |
Why?
| | Hyperoxia | 1 | 2026 | 99 | 0.220 |
Why?
| | Poverty | 2 | 2010 | 529 | 0.220 |
Why?
| | Longitudinal Studies | 10 | 2020 | 2947 | 0.220 |
Why?
| | Gliosis | 2 | 2023 | 29 | 0.220 |
Why?
| | Retrospective Studies | 15 | 2026 | 17066 | 0.220 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3890 | 0.220 |
Why?
| | Health Care Rationing | 1 | 2024 | 59 | 0.210 |
Why?
| | Brain Ischemia | 2 | 2017 | 358 | 0.200 |
Why?
| | Risk Assessment | 3 | 2026 | 3671 | 0.200 |
Why?
| | Disease Progression | 4 | 2026 | 2847 | 0.200 |
Why?
| | Denmark | 2 | 2021 | 50 | 0.200 |
Why?
| | Healthcare Disparities | 1 | 2010 | 727 | 0.200 |
Why?
| | Neurology | 1 | 2025 | 112 | 0.200 |
Why?
| | Medicaid | 1 | 2008 | 461 | 0.200 |
Why?
| | Oocytes | 2 | 2020 | 178 | 0.190 |
Why?
| | Proportional Hazards Models | 4 | 2025 | 1325 | 0.180 |
Why?
| | Body Mass Index | 6 | 2019 | 2438 | 0.180 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1326 | 0.180 |
Why?
| | Benchmarking | 1 | 2023 | 188 | 0.180 |
Why?
| | Pulmonary Fibrosis | 1 | 2026 | 395 | 0.180 |
Why?
| | Markov Chains | 3 | 2017 | 129 | 0.180 |
Why?
| | Monte Carlo Method | 3 | 2017 | 155 | 0.180 |
Why?
| | Prospective Studies | 9 | 2023 | 7990 | 0.170 |
Why?
| | Disability Evaluation | 4 | 2018 | 310 | 0.170 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 5868 | 0.170 |
Why?
| | Respiration, Artificial | 1 | 2026 | 708 | 0.170 |
Why?
| | Clinical Trials as Topic | 1 | 2026 | 1053 | 0.170 |
Why?
| | Doxycycline | 2 | 2011 | 62 | 0.160 |
Why?
| | Oxygen | 1 | 2026 | 995 | 0.160 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 16 | 0.160 |
Why?
| | Oocyte Donation | 1 | 2020 | 4 | 0.160 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 6 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 101 | 0.160 |
Why?
| | Healthy Aging | 1 | 2021 | 40 | 0.160 |
Why?
| | Prescription Drugs | 1 | 2022 | 111 | 0.160 |
Why?
| | Memory, Episodic | 1 | 2021 | 54 | 0.160 |
Why?
| | Weight Gain | 2 | 2022 | 556 | 0.160 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 124 | 0.160 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 43 | 0.160 |
Why?
| | Apomorphine | 3 | 2009 | 6 | 0.160 |
Why?
| | Proton Pump Inhibitors | 2 | 2017 | 109 | 0.150 |
Why?
| | Cross-Over Studies | 6 | 2025 | 601 | 0.150 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 206 | 0.150 |
Why?
| | Intensive Care Units | 1 | 2026 | 916 | 0.150 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1209 | 0.150 |
Why?
| | Fractals | 1 | 2019 | 8 | 0.150 |
Why?
| | Menstruation | 2 | 1991 | 42 | 0.150 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 22 | 0.150 |
Why?
| | Radial Nerve | 1 | 1999 | 10 | 0.150 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 22 | 0.150 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 75 | 0.150 |
Why?
| | Severity of Illness Index | 7 | 2024 | 2925 | 0.150 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3409 | 0.150 |
Why?
| | Human Growth Hormone | 2 | 2014 | 46 | 0.150 |
Why?
| | Internet | 2 | 2018 | 699 | 0.150 |
Why?
| | Astrocytes | 1 | 2021 | 222 | 0.140 |
Why?
| | Hip Fractures | 1 | 2019 | 84 | 0.140 |
Why?
| | Vital Capacity | 1 | 2019 | 290 | 0.140 |
Why?
| | Hypoxia | 1 | 2026 | 1199 | 0.140 |
Why?
| | Machine Learning | 1 | 2024 | 585 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 710 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2018 | 122 | 0.140 |
Why?
| | Quality of Life | 5 | 2018 | 3185 | 0.140 |
Why?
| | Bibliometrics | 1 | 2018 | 63 | 0.140 |
Why?
| | Sheep, Domestic | 1 | 2017 | 33 | 0.140 |
Why?
| | Regression Analysis | 2 | 2019 | 1003 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2021 | 3604 | 0.130 |
Why?
| | Eligibility Determination | 2 | 2008 | 68 | 0.130 |
Why?
| | Anxiety | 1 | 2025 | 1109 | 0.130 |
Why?
| | Wounds and Injuries | 1 | 2026 | 956 | 0.130 |
Why?
| | Contraception | 2 | 1991 | 169 | 0.130 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 1 | 0.130 |
Why?
| | Rhinitis | 2 | 2010 | 171 | 0.130 |
Why?
| | Medically Uninsured | 2 | 2008 | 129 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 760 | 0.130 |
Why?
| | Adolescent | 14 | 2024 | 22428 | 0.130 |
Why?
| | Algorithms | 3 | 2017 | 1837 | 0.130 |
Why?
| | Biomarkers | 5 | 2026 | 4271 | 0.130 |
Why?
| | Metabolic Diseases | 1 | 2018 | 114 | 0.120 |
Why?
| | Psychomotor Performance | 3 | 2009 | 328 | 0.120 |
Why?
| | Lactation | 1 | 2018 | 192 | 0.120 |
Why?
| | Family Planning Services | 2 | 2008 | 94 | 0.120 |
Why?
| | Hypothyroidism | 2 | 2007 | 67 | 0.120 |
Why?
| | Premature Birth | 1 | 2020 | 380 | 0.120 |
Why?
| | Affect | 3 | 2008 | 318 | 0.120 |
Why?
| | Ukraine | 2 | 2026 | 35 | 0.120 |
Why?
| | Low Back Pain | 1 | 2018 | 106 | 0.120 |
Why?
| | Sinusitis | 2 | 2010 | 228 | 0.120 |
Why?
| | Endoscopy | 2 | 2010 | 316 | 0.120 |
Why?
| | Double-Blind Method | 7 | 2011 | 2029 | 0.120 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 181 | 0.120 |
Why?
| | Antibodies | 1 | 2018 | 401 | 0.120 |
Why?
| | Pregnancy | 8 | 2023 | 7190 | 0.120 |
Why?
| | Models, Animal | 1 | 2017 | 392 | 0.120 |
Why?
| | Immunologic Memory | 1 | 2018 | 366 | 0.120 |
Why?
| | Dietary Fats | 1 | 2018 | 314 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 384 | 0.120 |
Why?
| | Brain | 6 | 2023 | 2933 | 0.110 |
Why?
| | Personnel Selection | 1 | 2016 | 93 | 0.110 |
Why?
| | Pulmonary Diffusing Capacity | 2 | 2026 | 78 | 0.110 |
Why?
| | Recovery of Function | 2 | 2010 | 707 | 0.110 |
Why?
| | Patient Dropouts | 1 | 2015 | 65 | 0.110 |
Why?
| | Otolaryngology | 1 | 2016 | 108 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 124 | 0.110 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 12 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 16 | 0.110 |
Why?
| | Inflammation | 1 | 2026 | 2878 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 244 | 0.110 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 165 | 0.110 |
Why?
| | Menstrual Cycle | 3 | 2011 | 140 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 142 | 0.100 |
Why?
| | Analysis of Variance | 5 | 2009 | 1306 | 0.100 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 212 | 0.100 |
Why?
| | Breast Feeding | 1 | 2018 | 448 | 0.100 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 779 | 0.100 |
Why?
| | Antibody Formation | 2 | 2022 | 294 | 0.100 |
Why?
| | Health Care Costs | 1 | 2017 | 427 | 0.100 |
Why?
| | Secretory Rate | 1 | 2013 | 12 | 0.100 |
Why?
| | Dementia | 2 | 2008 | 303 | 0.100 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 265 | 0.100 |
Why?
| | Health Policy | 2 | 2024 | 400 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1169 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 200 | 0.090 |
Why?
| | Electronics | 1 | 2013 | 71 | 0.090 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 202 | 0.090 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 361 | 0.090 |
Why?
| | Medical Records | 1 | 2013 | 187 | 0.090 |
Why?
| | Adenoma | 1 | 2014 | 218 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1694 | 0.090 |
Why?
| | Interviews as Topic | 3 | 2010 | 901 | 0.090 |
Why?
| | Age Factors | 8 | 2018 | 3333 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 392 | 0.090 |
Why?
| | Research Design | 3 | 2026 | 1135 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 541 | 0.090 |
Why?
| | Urban Health | 2 | 2009 | 96 | 0.090 |
Why?
| | Wakefulness | 1 | 2013 | 169 | 0.090 |
Why?
| | Treatment Outcome | 8 | 2024 | 11679 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 557 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 576 | 0.090 |
Why?
| | Progestins | 1 | 2011 | 87 | 0.080 |
Why?
| | Follow-Up Studies | 5 | 2017 | 5408 | 0.080 |
Why?
| | Equipment Design | 1 | 2013 | 530 | 0.080 |
Why?
| | Memory | 3 | 2008 | 295 | 0.080 |
Why?
| | Amenorrhea | 1 | 2011 | 31 | 0.080 |
Why?
| | Dopamine Agonists | 2 | 2008 | 42 | 0.080 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 30 | 0.080 |
Why?
| | Cytokines | 2 | 2015 | 2061 | 0.080 |
Why?
| | Birth Certificates | 1 | 2010 | 12 | 0.080 |
Why?
| | Estrone | 1 | 2010 | 40 | 0.080 |
Why?
| | Birth Rate | 2 | 2020 | 28 | 0.080 |
Why?
| | Insulin | 1 | 2022 | 2507 | 0.080 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 42 | 0.080 |
Why?
| | Electronic Health Records | 3 | 2026 | 1173 | 0.080 |
Why?
| | Cognition | 3 | 2008 | 1266 | 0.080 |
Why?
| | Automobile Driving | 2 | 2010 | 155 | 0.080 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 18 | 0.080 |
Why?
| | Live Birth | 2 | 2020 | 68 | 0.080 |
Why?
| | Geographic Information Systems | 2 | 2010 | 46 | 0.080 |
Why?
| | Pregnancy Rate | 2 | 2020 | 69 | 0.080 |
Why?
| | Diet | 1 | 2018 | 1273 | 0.080 |
Why?
| | Thyroxine | 2 | 2007 | 64 | 0.080 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 92 | 0.080 |
Why?
| | Colorado | 3 | 2025 | 4564 | 0.080 |
Why?
| | Cities | 1 | 2010 | 143 | 0.080 |
Why?
| | Personality | 1 | 2011 | 132 | 0.070 |
Why?
| | Sex Factors | 5 | 2018 | 2112 | 0.070 |
Why?
| | Abortion, Induced | 2 | 2008 | 110 | 0.070 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 9 | 0.070 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 39 | 0.070 |
Why?
| | United States | 6 | 2020 | 15966 | 0.070 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 74 | 0.070 |
Why?
| | Telecommunications | 1 | 2009 | 20 | 0.070 |
Why?
| | Independent Living | 1 | 2010 | 114 | 0.070 |
Why?
| | Progesterone | 3 | 2015 | 255 | 0.070 |
Why?
| | Registries | 1 | 2017 | 2385 | 0.070 |
Why?
| | Stroke | 1 | 2017 | 1256 | 0.070 |
Why?
| | Drug Interactions | 2 | 2007 | 398 | 0.070 |
Why?
| | Rural Health | 1 | 2009 | 87 | 0.070 |
Why?
| | Postmenopause | 1 | 2010 | 391 | 0.070 |
Why?
| | Anti-Bacterial Agents | 2 | 2026 | 1907 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 375 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 7 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 88 | 0.070 |
Why?
| | Logistic Models | 2 | 2010 | 2117 | 0.070 |
Why?
| | Ointments | 1 | 2007 | 25 | 0.070 |
Why?
| | Povidone-Iodine | 1 | 2007 | 11 | 0.070 |
Why?
| | Life Change Events | 1 | 2009 | 147 | 0.070 |
Why?
| | Foot | 1 | 2009 | 100 | 0.070 |
Why?
| | Vaccinia | 1 | 2007 | 20 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 23 | 0.070 |
Why?
| | Vaccinia virus | 1 | 2007 | 34 | 0.070 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 48 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 277 | 0.070 |
Why?
| | Exercise | 3 | 2010 | 2201 | 0.070 |
Why?
| | Child, Preschool | 4 | 2018 | 11787 | 0.060 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 43 | 0.060 |
Why?
| | Counseling | 1 | 2010 | 408 | 0.060 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 14 | 0.060 |
Why?
| | Atrophy | 1 | 2007 | 201 | 0.060 |
Why?
| | Population Surveillance | 1 | 2010 | 485 | 0.060 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 125 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 148 | 0.060 |
Why?
| | Antigens, Viral | 1 | 2007 | 182 | 0.060 |
Why?
| | Awareness | 1 | 2007 | 108 | 0.060 |
Why?
| | Movement | 1 | 2009 | 293 | 0.060 |
Why?
| | Albumins | 1 | 2007 | 118 | 0.060 |
Why?
| | Time Perception | 1 | 2007 | 33 | 0.060 |
Why?
| | Chemokine CXCL5 | 1 | 2026 | 19 | 0.060 |
Why?
| | Tremor | 1 | 2007 | 98 | 0.060 |
Why?
| | Chemokine CXCL9 | 1 | 2026 | 38 | 0.060 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 258 | 0.060 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 155 | 0.060 |
Why?
| | Hospitals, Community | 1 | 2026 | 65 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1257 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 634 | 0.060 |
Why?
| | Suicide, Attempted | 1 | 2009 | 422 | 0.060 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2026 | 133 | 0.060 |
Why?
| | Utah | 1 | 2025 | 81 | 0.060 |
Why?
| | Paroxetine | 1 | 2005 | 10 | 0.060 |
Why?
| | Infant | 3 | 2010 | 10034 | 0.060 |
Why?
| | Warfare | 1 | 2026 | 101 | 0.060 |
Why?
| | Treatment Failure | 2 | 2022 | 365 | 0.060 |
Why?
| | Animals | 7 | 2023 | 38058 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 2310 | 0.050 |
Why?
| | Attitude to Health | 1 | 2008 | 436 | 0.050 |
Why?
| | Neurologic Examination | 2 | 2008 | 131 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 405 | 0.050 |
Why?
| | Administration, Oral | 1 | 2007 | 847 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1985 | 0.050 |
Why?
| | Sexual Behavior | 1 | 2008 | 491 | 0.050 |
Why?
| | Length of Stay | 2 | 2026 | 1337 | 0.050 |
Why?
| | Health Promotion | 1 | 2010 | 774 | 0.050 |
Why?
| | Video Recording | 1 | 2025 | 212 | 0.050 |
Why?
| | Patient Compliance | 1 | 2008 | 588 | 0.050 |
Why?
| | Likelihood Functions | 2 | 2017 | 143 | 0.050 |
Why?
| | Amyloid beta-Peptides | 1 | 2026 | 241 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 203 | 0.050 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 12 | 0.050 |
Why?
| | Child | 5 | 2018 | 22633 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 854 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1720 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 50 | 0.050 |
Why?
| | Family | 1 | 2008 | 679 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 73 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 721 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2026 | 784 | 0.050 |
Why?
| | Physical Fitness | 1 | 2004 | 209 | 0.050 |
Why?
| | Vaccines | 1 | 2007 | 389 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 75 | 0.050 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 3 | 0.050 |
Why?
| | Facial Pain | 1 | 2002 | 12 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 578 | 0.050 |
Why?
| | Physical Examination | 2 | 2018 | 239 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 790 | 0.050 |
Why?
| | Urban Population | 1 | 2025 | 491 | 0.050 |
Why?
| | Acids | 1 | 2002 | 17 | 0.050 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 125 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2007 | 876 | 0.040 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 154 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2026 | 780 | 0.040 |
Why?
| | Odds Ratio | 3 | 2010 | 1075 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1356 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2025 | 302 | 0.040 |
Why?
| | Ovarian Follicle | 1 | 2002 | 73 | 0.040 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 175 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 176 | 0.040 |
Why?
| | Neuroimaging | 1 | 2023 | 289 | 0.040 |
Why?
| | Puberty | 1 | 2002 | 140 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3863 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2025 | 1030 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 12 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 18 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 284 | 0.040 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 126 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 214 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 408 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 885 | 0.040 |
Why?
| | Leptin | 1 | 2002 | 245 | 0.040 |
Why?
| | Blastocyst | 1 | 2020 | 47 | 0.040 |
Why?
| | Fasting | 1 | 2002 | 277 | 0.040 |
Why?
| | Embryo Transfer | 1 | 2020 | 37 | 0.040 |
Why?
| | Prostaglandins | 1 | 2000 | 94 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 112 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6048 | 0.040 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2452 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 2027 | 0.040 |
Why?
| | Critical Illness | 1 | 2026 | 891 | 0.040 |
Why?
| | Vaccination | 2 | 2024 | 1423 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 221 | 0.040 |
Why?
| | Oligodendroglia | 1 | 2001 | 187 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 116 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1414 | 0.040 |
Why?
| | Receptors, Nicotinic | 1 | 2001 | 321 | 0.030 |
Why?
| | Immunization, Secondary | 1 | 2018 | 91 | 0.030 |
Why?
| | Depression | 1 | 2008 | 1558 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2115 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 893 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.030 |
Why?
| | Milk | 1 | 2018 | 119 | 0.030 |
Why?
| | Depressive Disorder | 1 | 2000 | 387 | 0.030 |
Why?
| | Confidence Intervals | 2 | 2008 | 333 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 478 | 0.030 |
Why?
| | Protons | 1 | 2017 | 95 | 0.030 |
Why?
| | Biostatistics | 1 | 2017 | 19 | 0.030 |
Why?
| | Psychological Tests | 1 | 2018 | 132 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 73 | 0.030 |
Why?
| | Incidence | 2 | 2017 | 2879 | 0.030 |
Why?
| | Electromyography | 1 | 1999 | 415 | 0.030 |
Why?
| | Thyrotropin | 2 | 2007 | 118 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 261 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 985 | 0.030 |
Why?
| | Stem Cells | 1 | 2001 | 626 | 0.030 |
Why?
| | Health Surveys | 2 | 2009 | 518 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 863 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1382 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 851 | 0.030 |
Why?
| | Viruses | 1 | 2018 | 165 | 0.030 |
Why?
| | Drug Combinations | 2 | 2011 | 390 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 62 | 0.030 |
Why?
| | Telemedicine | 1 | 2025 | 945 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 216 | 0.030 |
Why?
| | Fatty Liver | 1 | 2018 | 251 | 0.030 |
Why?
| | Escherichia coli | 1 | 2000 | 854 | 0.030 |
Why?
| | Neoplasms | 1 | 2011 | 2875 | 0.030 |
Why?
| | Systole | 1 | 2015 | 178 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1489 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 42 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1217 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 127 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 276 | 0.030 |
Why?
| | Risk | 1 | 2017 | 911 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 529 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 213 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 734 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3162 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2018 | 652 | 0.020 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 128 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2015 | 395 | 0.020 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 230 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2015 | 769 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1143 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4557 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 965 | 0.020 |
Why?
| | Follicular Phase | 2 | 2004 | 38 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5992 | 0.020 |
Why?
| | Estrogens | 1 | 2015 | 380 | 0.020 |
Why?
| | Fatty Acids | 1 | 2015 | 450 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2018 | 684 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 775 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1539 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 382 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 675 | 0.020 |
Why?
| | Periodicity | 2 | 2001 | 58 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 4282 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 27 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 112 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 59 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 72 | 0.020 |
Why?
| | Amides | 1 | 2010 | 101 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 567 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 797 | 0.020 |
Why?
| | Income | 1 | 2010 | 202 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 213 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 175 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6429 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 2 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 736 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 11 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 18 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1129 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 178 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 454 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 197 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 37 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 42 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 18 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 312 | 0.020 |
Why?
| | Parity | 1 | 1988 | 109 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 56 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 19 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 880 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 10 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 26 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 158 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 21 | 0.020 |
Why?
| | Employment | 1 | 2010 | 188 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 26 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 48 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 222 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 151 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 91 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 164 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 467 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 79 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 471 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 75 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 576 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 47 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 172 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 508 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 404 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 54 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 94 | 0.020 |
Why?
| | Research | 1 | 2010 | 431 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 67 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 264 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 88 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 250 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 103 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2007 | 178 | 0.020 |
Why?
| | Age of Onset | 1 | 2008 | 551 | 0.010 |
Why?
| | Safety | 1 | 2008 | 356 | 0.010 |
Why?
| | Motor Skills | 1 | 2007 | 104 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 541 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2010 | 704 | 0.010 |
Why?
| | Dopamine Agents | 1 | 2005 | 22 | 0.010 |
Why?
| | Virus Diseases | 1 | 2007 | 216 | 0.010 |
Why?
| | Mental Recall | 1 | 2007 | 222 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 627 | 0.010 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 45 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1658 | 0.010 |
Why?
| | Self Efficacy | 1 | 2008 | 414 | 0.010 |
Why?
| | Memory, Short-Term | 1 | 2007 | 271 | 0.010 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 86 | 0.010 |
Why?
| | Vestibular Diseases | 1 | 2005 | 57 | 0.010 |
Why?
| | Dizziness | 1 | 2005 | 101 | 0.010 |
Why?
| | Inpatients | 1 | 2009 | 545 | 0.010 |
Why?
| | Diet Records | 1 | 2004 | 85 | 0.010 |
Why?
| | Menarche | 1 | 2004 | 52 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1813 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 293 | 0.010 |
Why?
| | Overweight | 1 | 2008 | 609 | 0.010 |
Why?
| | Skin | 1 | 2007 | 755 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 283 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 1152 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 5 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 33 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 24 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 222 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 37 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 34 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 167 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 57 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 2323 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 99 | 0.010 |
Why?
| | Dihydro-beta-Erythroidine | 1 | 2001 | 6 | 0.010 |
Why?
| | Fura-2 | 1 | 2001 | 10 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 118 | 0.010 |
Why?
| | Nifedipine | 1 | 2001 | 27 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 148 | 0.010 |
Why?
| | Nicotinic Antagonists | 1 | 2001 | 35 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 499 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 724 | 0.010 |
Why?
| | Caregivers | 1 | 2010 | 1049 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 46 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 330 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 3 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 3 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 16 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 402 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 165 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 3154 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 552 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2001 | 329 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2363 | 0.010 |
Why?
| | Fever | 1 | 2000 | 311 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1263 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1490 | 0.010 |
Why?
| | Calcium | 1 | 2001 | 1183 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 901 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2001 | 4154 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5597 | 0.010 |
Why?
| | Neurons | 1 | 2001 | 1640 | 0.010 |
Why?
| | Mice | 1 | 2007 | 18339 | 0.000 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|